Cosentyx is approved in Japan for treatment of Psoriasis and Psoriatic Arthritis- Novartis
Novartis announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved Cosentyx (secukinumab, formerly known as AIN 457), for the treatment of both Psoriasis vulgaris and Psoriatic Arthritis (PsA) in adults who are not adequately responding to systemic therapies (except for biologics). This approval marks the first country approval for Cosentyx in the world and makes it the first interleukin-17A (IL-17A) inhibitor to receive regulatory approval in either of these indications in Japan.
Cosentyx works by inhibiting the action of IL-17A, a protein that is found in high concentrations in skin affected by Psoriasis and central to the development of inflammatory diseases, including Psoriasis and PsA.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.